Alps is a Malaysia-based biotechnology and medical wellness company that operates two connected business lines: a network of medical aesthetics clinics and a pre-clinical R&D pipeline. The clinic business, managed through Alps Wellness Centre and Alps Medical Centre, provides surgical and non-surgical aesthetic treatments, hair transplants, and health screenings to patients in Kuala Lumpur. Another subsidiary, MyGenome, offers genomic services including whole genome sequencing and mRNA profiling. Alps uses the cash flow generated by these fee-for-service clinics to fund its biotechnology research, creating a self-funding model for its pre-clinical programs. The R&D pipeline targets cancer and chronic diseases through NK and CAR-T cell therapies, stem cell treatments for diabetes and heart failure, and mRNA-based cancer diagnostics. The company also develops exosome-based cosmetics and patient-derived organoids for personalized oncology. While the clinics generate all current revenue, Alps aims to eventually commercialize its therapeutic and diagnostic candidates. Celestialab, a company subsidiary, operates a cGMP-certified manufacturing facility to support these development efforts and future production. Alps leverages Malaysia’s regulatory environment and lower manufacturing costs to develop these treatments for the Southeast Asian market.